Artesunet50 mg

Artesunet is an artemisinin derivative antimalarial agent used for the treatment of malaria caused by Plasmodium falciparum and other Plasmodium species.

Established / Guideline-Supported Uses

• Severe (complicated) malaria - Intravenous (IV) or intramuscular (IM) Artesunet is the treatment of choice for severe malaria in adults and children, as recommended by the World Health Organization (WHO), and is FDA-approved in the United States for initial treatment of severe malaria.
• Uncomplicated P. falciparum malaria - Oral Artesunet is used only as part of artemisinin-based combination therapy (ACT), combined with a longer-acting partner drug (e.g., amodiaquine, mefloquine, sulfadoxine-pyrimethamine, or pyronaridine). Artesunet must never be used alone (as monotherapy) for uncomplicated malaria, because this promotes resistance.

Follow-on Treatment

After completion of IV/IM Artesunet for severe malaria, a complete course of an oral antimalarial (an ACT, atovaquone-proguanil, or doxycycline/clindamycin plus quinine) is required to complete the cure and prevent recrudescence.

Off-label: Artesunet is used off-label in some specialist settings for severe babesiosis unresponsive to standard therapy.

Each formulation of Artesunate contains artesunate (a semi-synthetic derivative of artemisinin, derived from the plant Artemisia annua) as the active ingredient.

• Injection (powder for reconstitution): Artesunate 60 mg (strengths vary by manufacturer) per vial, supplied with a separate sodium bicarbonate diluent ampoule.
• Oral tablet: Artesunate 50 mg or 100 mg per tablet, typically supplied as part of a fixed-dose or co-blistered combination pack with a partner antimalarial.

Excipients vary by manufacturer and formulation.

Artesunet is a water-soluble, semi-synthetic derivative of artemisinin, a sesquiterpene lactone endoperoxide originally isolated from the sweet wormwood plant, Artemisia annua. It is one of the fastest-acting antimalarial compounds available and is used to rapidly reduce parasite burden in both severe and uncomplicated malaria.

Artesunet is available as a powder for injection (for IV/IM use in severe malaria) and as oral tablets (used only in combination with a partner drug for uncomplicated malaria).

Artesunet belongs to the artemisinin derivative class of antimalarial agents (ATC code P01BE03), a subclass of the broader antimalarial/antiprotozoal drug group.

Mechanism

Artesunate is rapidly hydrolyzed in vivo to its active metabolite, dihydroartemisinin (DHA). The endoperoxide bridge of DHA is cleaved by intraparasitic heme released during hemoglobin digestion, generating carbon-centered free radicals that alkylate and damage parasite proteins and membranes, causing rapid death of the intra-erythrocytic parasite across a broad range of asexual stages, including early ring stages.

Pharmacokinetics

• Absorption: Rapidly absorbed after IV, IM, or oral administration.
• Metabolism: Converted to dihydroartemisinin (DHA) primarily by plasma and hepatic esterases; DHA is further metabolized by hepatic glucuronidation (mainly UGT1A9 and UGT2B7).
• Half-life: Artesunate itself has a very short half-life (minutes); DHA has a half-life of approximately 45 minutes to 1 hour.
• Elimination: Primarily via biliary/renal excretion of glucuronide metabolites.

Injectable Artesunet

Administered by slow intravenous injection (over 1-3 minutes) or by intramuscular injection into the anterior thigh. The powder must be reconstituted in two steps immediately before use (see Reconstitution) and used promptly; it is given as a direct injection, not mixed into a large-volume IV infusion bag.

Oral Artesunet

Tablets are swallowed with water, with or without food, at the same time each day as part of a combination antimalarial regimen. Do not crush combination tablets unless directed by the prescriber.

Clinically Significant Interactions

• Other antimalarials used in combination (e.g., mefloquine, amodiaquine, lumefantrine): These are intentionally co-administered as part of combination therapy, but the partner drug's own interaction and toxicity profile (e.g., mefloquine's neuropsychiatric effects, amodiaquine's hepatotoxicity/agranulocytosis risk) must be considered by the prescriber.
• Strong UGT1A9/UGT2B7 enzyme inducers (e.g., rifampicin): May theoretically alter clearance of the active metabolite dihydroartemisinin; clinical significance is not fully established but caution is advised.
• Other hepatotoxic drugs: Concurrent use may increase the risk of liver enzyme elevation; monitor liver function.

Always inform your physician of all other medicines, supplements, and herbal products you are taking before starting Artesunet.

Common

• Nausea, vomiting, diarrhea, abdominal pain
• Dizziness, headache
• Injection site pain or reaction (parenteral use)
• Mild, transient elevations in liver enzymes

Serious (Less Common)

• Post-treatment delayed hemolytic anemia - can occur 1 to 4 weeks after treatment of severe malaria with IV Artesunet, sometimes requiring blood transfusion; hemoglobin should be monitored weekly for at least 4 weeks after treatment (see Precautions and Warnings).
• Neutropenia
• Hypersensitivity reactions, including rare anaphylaxis
• QT interval changes (more often attributable to partner drugs used in combination therapy)

Pregnancy

Artesunet should be used in pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician must be consulted. For severe malaria in pregnancy, at any stage including the first trimester, WHO guidance and most experts recommend that IV/IM Artesunet should not be withheld, because untreated severe malaria carries a very high risk of maternal and fetal death that outweighs uncertain fetal risks of treatment. For uncomplicated malaria in the first trimester, alternative options may be preferred where available per local/WHO guidance, and the regimen should be individualized by the treating physician.

Lactation

Artesunet and its active metabolite pass into breast milk in small amounts. Breastfeeding is generally not discouraged during treatment given the importance of prompt malaria treatment, but a physician should be consulted, particularly for infants with known glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Post-Treatment Delayed Hemolytic Anemia

Delayed hemolysis has been reported, particularly after IV Artesunet treatment of severe malaria, typically emerging 1 to 4 weeks after treatment. Monitor hemoglobin/hematocrit weekly for at least 4 weeks after completing treatment, and evaluate promptly if signs of hemolysis (fatigue, jaundice, dark urine) develop.

Hypersensitivity

Stop Artesunet immediately and seek emergency care if signs of a hypersensitivity or anaphylactic reaction occur (see Contraindications).

Combination Therapy Requirement (Resistance Prevention)

Artesunet must always be given as part of combination therapy for uncomplicated malaria, never as monotherapy, in order to prevent the development and spread of artemisinin resistance. Strict adherence to the full prescribed combination-therapy course is essential.

Pregnancy - First Trimester

See Pregnancy and Lactation for guidance specific to first-trimester use.

Antimalarial Stewardship

Take Artesunet exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice, as incomplete or inappropriate use promotes drug resistance and treatment failure.

Limited data exist on Artesunet overdose. Suspected overdose may increase the risk of hemolysis, gastrointestinal symptoms, and other adverse effects described above. There is no specific antidote. If an overdose of Artesunet is suspected, seek immediate medical attention or contact emergency services/a poison control center; treatment is supportive, with close monitoring of hemoglobin, liver, and kidney function in a medical facility.

Injection (powder): Store at room temperature (below 30°C), protected from light and moisture, until ready to use. Once reconstituted, use immediately; discard any reconstituted or diluted solution not used within 1 hour. Oral tablets: Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

No formal dose adjustment is established; use with close monitoring, as severe malaria itself commonly causes acute kidney injury.

Hepatic Impairment

No formal dose adjustment is established; monitor liver function closely during and after treatment.

G6PD Deficiency

Use with caution and monitor for hemolysis; Artesunet-associated post-treatment hemolysis may be more pronounced in G6PD-deficient individuals.

Elderly

No specific dose adjustment is established for elderly patients; use with the same monitoring as in other adults, considering comorbidities.

Pediatric and Pregnant Patients

See Pediatric Uses and Pregnancy and Lactation sections.

For severe malaria, parenteral Artesunet is given for a minimum of 24 hours (at least 3 doses) and continued once daily until the patient can tolerate oral medication, followed immediately by a complete course (typically 3 days) of an oral antimalarial to complete the cure. For uncomplicated malaria, oral Artesunet-based combination therapy is typically given for 3 days in total. The full prescribed duration must always be completed, even if symptoms improve earlier.

Two-Step Reconstitution (Injectable Artesunet)

Step 1: Reconstitute the Artesunet powder with the supplied 5% sodium bicarbonate diluent and shake/swirl until the powder fully dissolves into a clear solution (artesunic acid).

Step 2: Further dilute this solution with either 5% dextrose injection or 0.9% sodium chloride injection to the volume specified by the manufacturer's instructions, immediately before administration.

The reconstituted and diluted solution should be used within 1 hour of preparation; discard any unused portion. Do not use if the solution is cloudy or contains particulate matter.

Antimalarial agent - Artemisinin derivative (semi-synthetic sesquiterpene lactone endoperoxide).

Artesunate is converted in the body to dihydroartemisinin (DHA), its active form. The endoperoxide bridge within DHA reacts with iron released from heme inside the malaria parasite's food vacuole, generating reactive free radicals. These radicals alkylate parasite proteins and disrupt parasite membrane function, killing the parasite rapidly across multiple stages of its erythrocytic life cycle, including early ring-stage parasites that other antimalarials act on less effectively. This rapid, broad-stage action is why Artesunate reduces parasite burden faster than most other antimalarial classes.

Artesunet is used for severe malaria in pediatric patients of all ages and body weights, with weight-based IV/IM dosing (3 mg/kg per dose for children weighing less than 20 kg, at 0, 12, 24 hours then once daily), per WHO guidance and FDA labeling for the injectable product. For uncomplicated malaria, oral Artesunet-based combination therapy is used in children per the weight-based dosing of the specific combination product prescribed. Safety and efficacy of oral Artesunet combination products in neonates are less well established; treatment decisions in very young infants should be made by a pediatric/infectious disease specialist. Close monitoring for post-treatment hemolysis applies to children as it does to adults.